Literature DB >> 22083345

Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer.

Mark J Dobrzanski1, Kathleen A Rewers-Felkins, Khaliquzzaman A Samad, Imelda S Quinlin, Catherine A Phillips, William Robinson, David J Dobrzanski, Stephen E Wright.   

Abstract

Adoptive T cell therapy for cancer patients optimally requires participation of CD4 T cells. In this phase I/II study, we assessed the therapeutic effects of adoptively transferred IL-10- and IFN-γ-producing CD4 effector cells in patients with recurrent ovarian cancer. Using MUC1 peptide and IL-2 for ex vivo CD4 effector cell generation, we show that three monthly treatment cycles of autologous T cell restimulation and local intraperitoneal re-infusion-modulated T cell-mediated immune responses that were associated with enhanced patient survival. One patient remains disease-free, another patient experienced prolonged survival for nearly 16 months with recurrent disease, and two patients expired within 3-5 months following final infusion. Prolonged survivors showed elevated levels of systemic CD3(+)CD4(+)CD25(+) and CD3(+)CD4(+)CD25(-) T cells when compared to that of pre-treatment levels and similarly treated short-term survivors. Such cell populations among these patients contained variable levels of "Inducible" Tr1 (CD4(+)CD25(-)FoxP3(-)IL-10(+)) and "Natural" (CD4(+)CD25(+)CD45RO(+)FoxP3(+)) TReg cell numbers and ratios that were associated with prolonged and/or disease-free survival. Moreover, peptide-restimulated T cells from these patients showed an elevation in both IFN-γ production, memory cell phenotype, and select TNF family ligands associated with enhanced T cell survival and apoptosis-inducing activities. This suggests that intraperitoneally administered Th1-like cells, producing elevated levels of IL-10, may require and/or induce differential levels of distinct systemic TReg subpopulations that influence, in part, long-term tumor immunity and enhanced memory/effector CD4-mediated therapeutic potentials. Furthermore, treatment efficacy and enhanced memory cell phenotype did not appear to be dependent on TReg cell numbers but upon ratios of "Inducible" and "Natural" TReg subpopulations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22083345      PMCID: PMC3315597          DOI: 10.1007/s00262-011-1128-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  79 in total

1.  The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

Authors:  Dominik Wolf; Anna M Wolf; Holger Rumpold; Heidi Fiegl; Alain G Zeimet; Elisabeth Muller-Holzner; Martina Deibl; Guenther Gastl; Eberhard Gunsilius; Christian Marth
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

2.  Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity.

Authors:  Noriko Komatsu; Maria Encarnita Mariotti-Ferrandiz; Ying Wang; Bernard Malissen; Herman Waldmann; Shohei Hori
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

Review 3.  IL-10 production by CD4+ effector T cells: a mechanism for self-regulation.

Authors:  D Jankovic; D G Kugler; A Sher
Journal:  Mucosal Immunol       Date:  2010-03-03       Impact factor: 7.313

Review 4.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

5.  CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice.

Authors:  Susan E Erdman; Jane J Sohn; Varada P Rao; Prashant R Nambiar; Zhongming Ge; James G Fox; David B Schauer
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

Review 6.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

7.  Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells.

Authors:  Stephen E Wright; Kathleen A Rewers-Felkins; Imelda S Quinlin; Paul W Eldridge; Paul E Zorsky; Panpit P Klug; Catherine A Phillips; Ramila Philip
Journal:  Int J Mol Med       Date:  2002-04       Impact factor: 4.101

Review 8.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

9.  Generation of MUC1-stimulated mononuclear cells using optimized conditions.

Authors:  S E Wright; R Khaznadar; Z Wang; I S Quinlin; K A Rewers-Felkins; C A Phillips; S Patel
Journal:  Scand J Immunol       Date:  2007-11-15       Impact factor: 3.487

Review 10.  The role of TNF superfamily members in T-cell function and diseases.

Authors:  Michael Croft
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

View more
  15 in total

Review 1.  Targeted immune therapy of ovarian cancer.

Authors:  Keith L Knutson; Lavakumar Karyampudi; Purushottam Lamichhane; Claudia Preston
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

2.  Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies.

Authors:  Zinnia P Parra-Guillen; Pedro Berraondo; Emmanuel Grenier; Benjamin Ribba; Iñaki F Troconiz
Journal:  AAPS J       Date:  2013-04-19       Impact factor: 4.009

Review 3.  TGFβ in T cell biology and tumor immunity: Angel or devil?

Authors:  Eric Tu; Pei Zhi Cheryl Chia; Wanjun Chen
Journal:  Cytokine Growth Factor Rev       Date:  2014-07-29       Impact factor: 7.638

Review 4.  Cancer-associated mucins: role in immune modulation and metastasis.

Authors:  Rakesh Bhatia; Shailendra K Gautam; Andrew Cannon; Christopher Thompson; Bradley R Hall; Abhijit Aithal; Kasturi Banerjee; Maneesh Jain; Joyce C Solheim; Sushil Kumar; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

5.  Interleukin-10 Modulation of Virus Clearance and Disease in Mice with Alphaviral Encephalomyelitis.

Authors:  Nina M Martin; Diane E Griffin
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

6.  Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression.

Authors:  Raoul J P Bonnal; Grazisa Rossetti; Enrico Lugli; Marco De Simone; Paola Gruarin; Jolanda Brummelman; Lorenzo Drufuca; Marco Passaro; Ramona Bason; Federica Gervasoni; Giulia Della Chiara; Claudia D'Oria; Martina Martinovic; Serena Curti; Valeria Ranzani; Chiara Cordiglieri; Giorgia Alvisi; Emilia Maria Cristina Mazza; Stefania Oliveto; Ylenia Silvestri; Elena Carelli; Saveria Mazzara; Roberto Bosotti; Maria Lucia Sarnicola; Chiara Godano; Valeria Bevilacqua; Mariangela Lorenzo; Salvatore Siena; Emanuela Bonoldi; Andrea Sartore-Bianchi; Alessio Amatu; Giulia Veronesi; Pierluigi Novellis; Marco Alloisio; Alessandro Giani; Nicola Zucchini; Enrico Opocher; Andrea Pisani Ceretti; Nicolò Mariani; Stefano Biffo; Daniele Prati; Alberto Bardelli; Jens Geginat; Antonio Lanzavecchia; Sergio Abrignani; Massimiliano Pagani
Journal:  Nat Immunol       Date:  2021-05-20       Impact factor: 25.606

Review 7.  IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.

Authors:  Ramesh B Batchu; Oksana V Gruzdyn; Bala K Kolli; Rajesh Dachepalli; Prem S Umar; Sameer K Rai; Namrata Singh; Pavan S Tavva; Donald W Weaver; Scott A Gruber
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy.

Authors:  Mark J Dobrzanski
Journal:  Front Oncol       Date:  2013-03-26       Impact factor: 6.244

9.  Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer.

Authors:  Zhenyao Wang; Monte D Hall; Kathleen A Rewers-Felkins; Imelda S Quinlin; Stephen E Wright
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

Review 10.  MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.

Authors:  David Roulois; Marc Grégoire; Jean-François Fonteneau
Journal:  Biomed Res Int       Date:  2012-12-26       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.